Lung Cancer Drugs Market Report 2025

This Lung Cancer Drugs market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The lung cancer drugs market size has grown rapidly in recent years. It will grow from $47.94 billion in 2024 to $54.13 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to epidemiology and demographics, regulatory approvals, healthcare infrastructure, patient awareness and education.

The lung cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $82.14 billion in 2029 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to health insurance and reimbursement policies, healthcare infrastructure and access, emerging markets. Major trends in the forecast period include advancements in targeted therapies, immunotherapy, genomic profiling, clinical trials and research.

The increasing prevalence of lung cancer serves as a significant growth driver for the lung cancer drugs market. This trend is primarily attributed to the rising incidence of lung cancer cases, which necessitates the development and availability of drugs for efficient and rapid disease treatment. Consequently, the industry maintains a robust drug pipeline to address this growing demand. As of January 2023, the American Cancer Society reported an estimated 238,340 new lung cancer cases, with 127,070 deaths from lung cancer expected in the same year. These figures indicate the increasing prevalence of lung cancer, thus fueling the expansion of the lung cancer drugs market.

The growth of the lung cancer drugs market is further propelled by the increasing prevalence of smoking. Smoking, a leading cause of lung cancer, is linked to inhaling and exhaling fumes from burning plant material, particularly tobacco in various forms like cigarettes, cigars, or pipes. For instance, in 2022, according to the Global Action to End Smoking, a US-based non-profit organization, an estimated 253 million people aged 15 and older in India were tobacco users, making it one of the countries with the highest number of tobacco users globally. Consequently, the rising prevalence of smoking is contributing to the growth of the lung cancer drugs market.

The lung cancer drugs market is witnessing an emerging trend in targeted drug therapy in combination with other treatment modalities. This approach involves the utilization of immunotherapy drugs alongside other therapies like chemotherapy to enhance early diagnosis, prevention, and treatment of lung cancer. Leading pharmaceutical manufacturers are actively developing targeted drug therapies to improve the diagnostic and treatment processes for lung cancer. For instance, Merck and Co. have introduced pembrolizumab, a drug that boosts the immune system's ability to identify and combat cancer cells when used in conjunction with chemotherapy. This combination therapy has demonstrated promising outcomes in the management of lung cancer, and it is prominently marketed under the brand name Keytruda.

Major companies operating in the lung cancer drugs market are placing a strong emphasis on the introduction of novel drugs and obtaining regulatory approvals to gain a competitive advantage. The approval of new drugs is a comprehensive process involving requests from pharmaceutical manufacturers or their representatives to regulatory agencies such as the US Food and Drug Administration (FDA). This request is made for the final utilization and commercialization of a new drug for specific indications. As an illustration, in November 2022, Regeneron Pharmaceuticals Inc., a prominent biotechnology firm, announced the FDA's approval of the PD-1 inhibitor Libtayo (cemiplimab-rwlc) for use in combination with platinum-based chemotherapy as the first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC). This approval encompasses patients with locally or metastatically advanced malignancies that are not amenable to definitive chemoradiation or surgical excision. Furthermore, this combination treatment is suitable for patients regardless of histology or PD-L1 expression.

The FDA's regulatory guidelines for lung cancer drugs are delineated in the Code of Federal Regulations (CFR), specifically under Title 21, encompassing subparts from 'A' to 'I'. Subpart 'E' focuses on procedures intended to facilitate the development, assessment, and marketing of drugs designed to treat individuals with life-threatening conditions like lung cancer. These regulations include guidelines for the oversight and evaluation of clinical trials involving lung cancer drugs and other cancer treatments by agency officials. These evaluations aim to determine the safety, efficacy, and comparative benefits of new therapies when compared to existing treatments. Compliance with these FDA regulations is a mandatory requirement for all drug manufacturers in the realm of lung cancer drugs. Consequently, these regulations play a pivotal role in overseeing the activities of lung cancer drug manufacturers and ensuring adherence to rigorous safety and efficacy standards.

Lung cancer drugs are a class of anti-angiogenic medications utilized for the treatment of lung cancer, a disease that disrupts the lungs' oxygen supply due to the uncontrolled growth of lung tissues. Potential treatments for lung cancer encompass surgical procedures, chemotherapy, radiation therapy, and targeted therapies. Lung cancer is broadly categorized into two types based on the size of tumor cells such as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

The primary disease categories within the lung cancer drugs sector are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Small cell lung cancer is characterized by rapid growth in lung tissues and often presents with metastasis beyond the lungs at the time of diagnosis. It has a higher likelihood of recurrence after treatment compared to other lung cancer types. Various drugs are used in the treatment of these cancers, including Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, and others. These drugs find application in healthcare settings such as hospitals, clinics, and other medical facilities.

The lung cancer drugs market research report is one of a series of new reports that provides lung cancer drugs market statistics, including lung cancer drugs industry, global lung cancer drugs market size, regional shares, competitors with a lung cancer drugs market share, detailed lung cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer drugs industry. This lung cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the lung cancer drugs market include Bristol-Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., GlaxoSmithKline PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Celgene Corporation, Mylan N.V., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ziopharm Oncology Inc., Menarini Group, AstraZeneca PLC, Shanghai Jinhe Bio-Technology Co. Ltd., Nlyte Software, AbbVie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eli Lilly and Company Inc., Johnson & Johnson, Amgen Inc., Array BioPharma Inc., Astellas Pharma Inc., Biogen Inc., Clovis Oncology Inc., Eisai Co. Ltd., Exelixis Inc., Genentech Inc., Gilead Sciences Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., Jazz Pharmaceuticals PLC, Karyopharm Therapeutics Inc., Kyowa Kirin Co. Ltd., Loxo Oncology Inc., MedImmune LLC.

North America was the largest region in the lung cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the lung cancer drugs market during the forecast period. The regions covered in the lung cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lung cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The lung cancer drugs market consists of sales of bevacizumab, atezolizumab, and ramucirumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.